Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA director Jean-Michel Cossery filed an initial ownership report showing his equity stake in the company. He directly holds 186,488 ordinary shares, including 33,784 shares to be delivered from a restricted share unit award that vests at the next annual shareholder meeting, subject to continued service.
He also holds share options over 59,880 ordinary shares at an exercise price of 2.5300, expiring on October 2, 2033, which vest in thirds annually on the date of the company’s annual shareholder meeting. A further option covers 49,751 ordinary shares at an exercise price of 3.0400, expiring on June 18, 2035, vesting 100% at the next scheduled annual shareholder meeting, also subject to continued service.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported his initial ownership on a Form 3. He directly holds 92,419 ordinary shares, including 30,405 shares issuable upon settlement of five restricted stock unit grants that vest over time with continued service.
He also holds several vested and unvested share options to buy ordinary shares at exercise prices ranging from 3.29 to 18.00, with expiration dates from 2029 through 2035. These option and RSU awards reflect his equity-based compensation and align part of his pay with the company’s share performance.
SOPHiA GENETICS SA filed an initial ownership report for Chief Legal Officer Daan Van Well, outlining his equity position in the company. He directly holds 261,922 ordinary shares, which includes 97,620 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time based on continued service. He also holds several option awards to buy ordinary shares, with exercise prices ranging from $3.29 to $18.00 per share and expiration dates between 2029 and 2035, providing long-term equity exposure but reflecting holdings rather than new market transactions.
SOPHiA GENETICS SA director Didier Hirsch filed an initial ownership report. He holds 220,496 ordinary shares, including 33,784 shares to be delivered upon settlement of a restricted share unit award that vests in full at the company’s next annual shareholders’ meeting, subject to continued service.
He also holds fully vested and exercisable share options over 140,000 ordinary shares at an exercise price of 4.2100 per share expiring on June 25, 2030, and options over 49,751 ordinary shares at 3.0400 per share expiring on June 18, 2035.
SOPHiA GENETICS SA director Vincent Ossipow filed an initial ownership report showing 503,136 ordinary shares held directly, including 33,784 shares to be delivered under a restricted share unit award that vests at the next annual shareholder meeting.
He also holds fully vested, exercisable share options over 60,000 ordinary shares at an exercise price of $6.31 expiring on January 28, 2031, and options over 49,751 ordinary shares at $3.04 expiring on June 18, 2035.
SOPHiA GENETICS SA Chief Executive Officer Camblong Jurgi has filed a Form 3 reporting his initial ownership in the company. He directly holds 3,307,325 ordinary shares, including 616,351 ordinary shares issuable upon settlement of restricted stock units that vest over time, and 891,320 ordinary shares have been pledged under lending arrangements. He also reports several share options giving rights to buy additional ordinary shares at exercise prices ranging from 3.1600 to 18.0000 per share, with expirations between late 2028 and early 2035. Certain option and RSU awards vest in scheduled monthly or quarterly installments through 2028.
SOPHiA GENETICS SA filed an initial ownership report for Chief Scientific Officer Xu Zhenyu, detailing his existing equity position. He directly holds 537,724 ordinary shares, including 115,002 shares issuable under restricted stock units that vest over time, and 147,840 shares that have been pledged under lending arrangements. He also holds multiple share options over ordinary shares with expirations ranging from 2027 to 2035; some options are already fully vested, while others vest in monthly or quarterly installments through dates specified in the footnotes. The filing lists these holdings and does not show any new purchases or sales.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma filed an initial Form 3 reporting his equity holdings in the company. He directly holds 125,813 ordinary shares, which include 80,762 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time through dates extending to April 2, 2028.
Verma also holds several share options over ordinary shares: 31,847 at an exercise price of $8.36 expiring March 30, 2032, 130,112 at $4.72 expiring April 3, 2033, 182,927 at $4.96 expiring April 2, 2034, and 136,364 at $3.29 expiring April 2, 2035. These options vest in stages, with portions becoming exercisable on specific dates and the remainder vesting in equal monthly installments through 2027.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza filed an initial ownership report showing his equity position in the company. He holds 185,632 Ordinary Shares directly. He also holds share options over 183,333 Ordinary Shares at an exercise price of $3.4000 per share, expiring on December 18, 2034, and separate share options over 187,500 Ordinary Shares at an exercise price of $3.2900 per share, expiring on April 2, 2035. Footnotes state that 70,826 additional Ordinary Shares are issuable upon settlement of restricted stock units, vesting over time subject to his continued service.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu filed an initial ownership report showing direct holdings of 174,224 ordinary shares. This figure includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time, subject to continued service. He also reports several share option awards over ordinary shares with various exercise prices and expirations between 2030 and 2035, providing additional potential equity exposure if exercised in the future.